12:00 AM
 | 
Nov 05, 2012
 |  BC Week In Review  |  Company News  |  Deals

BioMarin, Catalyst Pharma deal

BioMarin granted Catalyst exclusive, North American rights to Orphan drug Firdapse amifampridine. BioMarin, which is eligible for undisclosed royalties, will invest $5 million in Catalyst to support development of Firdapse in the U.S. Catalyst will be responsible for all other future costs of developing and commercializing Firdapse in North America...

Read the full 236 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >